OMER Omeros Corp

$OMER i am blaming Greg for this upward movement how dare you produce 32M revenue when only 12M was expected. I am sure you will continue to bring value to this company. Cheers!!

$OMER just normal fluctuations in between earnings… nothing has changed. After third-quarter results will be sitting closer to $25-27. Feel free to mark this post.

$OMER have a nice weekend my friends, most of us can upgrade from Top Ramen this weekend 🍜

$OMER Who honestly would’ve bet more than a dollar that we’d hit $32M in gross sales before the earnings call? Still unbelievable.

$OMER This type of Resilience in the face of a bad biotech day is really great and different action compared to normal omer , Things are only looking up from here. 1) Increasing Sales of Yart as J-Code and then NTAP on Oct 1st Take effect. 2) Next Phase of 527 Begins this Year 3) Yart ARDS trials begins this year 4) Novo starts Zaltenibart Phase 3 next year. 5) OncotoX Phase 1 next year = Profit!

$OMER GD knew about the in-the-money options likely to be exercised by directors/senior management and non-reportable staff. options. He had stellar sales data for the 2nd quarter, but also knows how it is tracking into the 3rd quarter with +J-code in place and NTAP soon coming on line. He closed the quarter with $132M. I firmly believe that in the period between July 1st and August 12th GD was buying OMER shares cheaply to cover exercise of employees' options and also to buy back premptively shares to cover balance of future convertible notes conversion. These purchases are not reportable until 3rd Quarter earnings report. They reduce the shares available for short covering, and prevent normal dilution. GD you've done it again: no favours for anyone, except true believers.

$OMER I started buying this stock in Aug 2021. My first purchase 500 shares at $15.13. I bought shares pretty regularly as it was on a fast elevator down. A little over a year later, December 2022, I bought 1000 shares at $1.98. For the following 3 years as the news didn't get a lot better I bought shares between $3-$5. For a very long time this stock was a drag on my portfolio. It is finally looking really good and making me look smarter. A lot of people say buy and hold doesn't work in biotech. That may be the case frequently but I'd argue that if the science is good then buy and then buy more when news isn't favorable over time. Flipping these stocks creates tax consequences, and it is hard to to time things well on a consistent basis. Sometime in the not too distant future I plan to start to leg out of this investment just like I bought into it, and realize the gains. Cheers to all those who have been patient with OMER! It is now a wealth creator in my portfolio!

$OMER Hard to believe that 2 months ago we were under $9. Thinking much more to go here! Continue to add on any pullback while selling puts and calls along the way! No extra charge...for those concerned about the execs cashing in options, remember, they can not trade on insider information. The recent insider sales are nothing burgers.

$OMER that’s the beauty of the ARDS study/trial - they don’t need the FDA approval for it to be massively successful in ARDS. They just have to show it works and get a study review from a top shelf publication. Then doctors will write the script off label - you don’t necessarily need FDA approval for ARDS to get the scripts going and revenue to ramp. Now, the study will have to be appropriately sized 100+ patients and they will have to show mortality reduction vs the base case mortality in hyper inflammatory ARDS of 45-50%. We know from Covid/ispy Yartemlea mortality was around 10% - if it’s anywhere near that mortality rate vs the current 45-50% this is a home run - it would become standard of care hands down. It could become the standard of care if it produces a mortality of 30% or less IMO. Imagine if they used it before patients had to go onto a ventilator!!! Prophylactic use would push revenues higher than any of us can imagine - similar for TA- TMA

$OMER SOLD…i turned 30k into 93k😭Im going to pay for my daughters school and buy my son his first car……know i sold early but i just couldnt handle the pressure anymore😭

$OMER I believe the ARDS Trial starting in December is the reason for the rise in price and shares getting thin. If ARDS works this is a thousand dollar stock. 🤷‍♂️

$OMER Price per share after third-quarter results= ~$26 After fourth-quarter results= ~$35 * Unknown timing of hundred million infusion from NBO= +$3 End of year probable price= ~$38-43

$OMER “Omeros Corporation is participating as an exhibitor (Booth 132) at the Fourteenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2026). The conference takes place from September 9 to 12, 2026, at the George R. Brown Convention Center in Houston, Texas. At the event, Omeros Corporation is highlighting its clinical and commercial developments, including its lead complement inhibitor YARTEMLEA (narsoplimab-wuug), which is approved for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA.” This is AI generated. What is sure is that in 2025 they didn’t participate but this year they do. More AI: While a formal abstract presentation for OncotoX-AML is not on the SOHO leukemia program, company representatives at Booth 132 will be equipped to provide the latest high-level commentary on when this program is expected to transition into human clinical trials.

$OMER Trading very well considering absolutely little to no volume day. We seem destined for next move up which as we know normally see 1.5- 2M shares traded. In the past we would get torched on these low volume days like this. Cant help to be very optimistic these next few weeks.

$OMER i own a large core at a low price but i dont see a better play elsewhere. im going to continue dollar cost averaging unless something fundamentally changes. this is primed for substantial growth.

$OMER Must be tough to be short here. We could wake up tomorrow morning to the $100M from Novo. We could wake up to a positive development from the EU. W/J-Code active, many tailwinds to get us to a more appropriate equilibrium price.

$OMER Wow, oh happy days Omerites!! “ I think I can make it now, the pain is gone All of the bad feelings have disappeared Here is the rainbow I've been prayin' for It's gonna be a bright (bright), bright (bright)Sun-shiny day!!!” I remember buying some of my shares at $22/25 10 years ago fortunately not many, but my oh my how the story has changed from Omidria to Yartemlia. Congrats to the longs & more sunshine coming our way with obstacles falling left & right!!! Exceptionally

$OMER this isn't the old Omeros anymore. OMER 2.0 is a Beast and will fight back when messed with!

$OMER Unless u r a day trader, u should not sell now. Drug works. That is now confirmed beyond a doubt. We are de-risked completely except the macroeconomics. Stick to your shares and enjoy the ride over the next 2-3 years until GD is ready to sell

$OMER - ZALTENIBART -The development and financial milestones for zaltenibart are governed by a multi-billion-dollar licensing agreement. In late 2025, Novo Nordisk acquired the exclusive global rights to the drug from Omeros Corporation. The clinical milestone targets and the subsequent financial payouts are structured as follows: 1. Clinical & Regulatory Milestones • Phase 3 Clinical Data: Novo Nordisk is managing the global Phase 3 clinical trials evaluating the drug for paroxysmal nocturnal hemoglobinuria (PNH). Topline clinical data required for regulatory approval is anticipated in late 2027. • Biologics License Application (BLA): Following successful trial readouts, a BLA submission to the FDA for PNH is expected to occur around the fourth quarter of 2027. • Indication Expansion: Beyond PNH, development milestones are tied to expanding the drug's clinical pipeline into other rare kidney and blood conditions, such as C3 glomerulopathy (C3G) and IgA nephropathy.